Clinical trials: Intervention Phase
Healthy Volunteers
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition
The purpose of this study is to look at safety, tolerability, and pharmacodynamic effects (i.e. how the study drug affects your body) of PF-07258669 in older participants ((60 years to <90 years) including those at risk of…
- Trial name
- NCT07086664
- Testing
- PF-07258669
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1
The purpose of this study is to characterize the delayed-type hypersensitivity (DTH) response at the site of Candin intradermal injection in the presence of a targeted immune pathway inhibitor.
- Trial name
- PLATFORM (NCT04589026)
- Testing
- Cosentyx, Candin
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Ovarian Neoplasms, Peritoneal Neoplasms
An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary…
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01932125
- Testing
- Bevacizumab
- Where
- 13 sites in India
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus
The purpose of this observational study is to estimate the overall survival (OS) rates in the overall study population treated with nivolumab in the second and third line setting in real world clinical practice in Greece and…
- Trial name
- LUCENCE (NCT05034926)
- Where
- 2 sites in Cyprus, Greece
- Volunteers
- 212 people
- Sponsor
- Bristol-Myers Squibb
Iron Overload
Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
This study employed a prospective, single-arm, global multi-center interventional open-label, non-randomized design to identify and assess safety profile of the crushed deferasirox FCT when administered up to 24 weeks in…
- Trial name
- MIMAS (NCT03372083)
- Testing
- Deferasirox
- Where
- 10 sites in Egypt, Italy and 5 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Postoperative Nausea and Vomiting
A Study of Vestipitant (GW597599) in the Treatment of Breakthrough Postoperative Nausea and Vomiting (PONV)
This study will evaluate single IV doses of Vestipitant (GW597599) compared to 4 mg IV ondansetron for treating breakthrough postoperative nausea and vomiting (PONV) after failure of PONV prophylaxis with a regimen that includes…
- Trial name
- NCT01507194
- Testing
- Ondansetron, Vestipitant
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- Accenture
Metastatic Hormone-sensitive Prostate Cancer
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor…
- Trial name
- NCT06991556
- Testing
- JSB462, Abiraterone, Enzalutamide
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 168 people
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Disease, Thrombosis
Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two cohorts.
- Trial name
- NCT03963895
- Testing
- AB002 Dose 1, AB002 Dose 2
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Aronora, Inc.
Intraoperative Ureter Injury
Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery
The purpose of this clinical trial is to study the safety and efficacy of an investigational imaging agent for delineation/visualization of urologic anatomy in the setting of minimally invasive surgery.
- Trial name
- NCT03106038
- Testing
- Nerindocianine for Injection
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Li-Cor, Inc.
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer
Percutaneous Coronary Intervention, Coronary Artery Disease (CAD)
Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
The study investigates the safety and efficacy of PMX-60056 for the Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
- Trial name
- NCT01312935
- Testing
- PMX-60056
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- PolyMedix, Inc.
Percutaneous Coronary Intervention
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI.
- Trial name
- INNOVATE-PCI (NCT00751231)
- Testing
- clopidogrel, PRT060128
- Where
- 59 sites in United States, Austria and 3 more
- Volunteers
- 652 people
- Sponsor
- Portola Pharmaceuticals
Lipodystrophies, Aesthetics Procedure
Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid
Lipodystrophies are part of a clinically heterogeneous group of disorders characterized by loss (lipoatrophies) and / or accumulation of fat, which usually results in a change of normal tissue surface.
- Trial name
- LipAge (NCT02034786)
- Testing
- Adipose tissue collection, Transdermal injection
- Where
- Brazil
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Cryopraxis Criobiologia Ltda.
Multiple Sclerosis
A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis
The main purpose of this study is to investigate Lu AG06466 as a treatment for spasticity in participants with multiple sclerosis (MS).
- Trial name
- NCT04990219
- Testing
- Lu AG06466
- Where
- 7 sites in United States, Germany
- Volunteers
- 37 people
- Sponsor
- H. Lundbeck A/S
Relapsing-Remitting Multiple Sclerosis (RRMS)
Plegridy Satisfaction Study in Participants
The primary objective of this study is to investigate whether Peg-IFN beta-1a improves the satisfaction of Relapsing-Remitting Multiple Sclerosis (RRMS) participants unsatisfied with injectable subcutaneous Interferons, as…
- Trial name
- PLATINUM (NCT02587065)
- Testing
- peginterferon beta-1a
- Where
- 30 sites in Italy
- Volunteers
- 193 people
- Sponsor
- Biogen
Spinal Disorder
An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders
The purpose of this study is to assess the pain reduction rate after 8 weeks treatment of NORSPAN® from baseline. And secondary purpose are: pain reduction rate after 4 weeks treatment from baseline(week 0) the EQ-5D, the pain…
- Trial name
- NOBLE (NCT01818700)
- Testing
- Buprenorphine
- Where
- South Korea
- Volunteers
- 245 people
- Sponsor
- Mundipharma Korea Ltd
Lymphoma, Follicular
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) in previously untreated patients with follicular lymphoma. Data will be collected for 3 years
- Trial name
- NCT01609036
- Where
- 4 sites in Greece
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy Secondary to Age-related Macular Degeneration
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
This is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD).
- Trial name
- Opti-GAIN (NCT07392255)
- Testing
- CTx001
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Complement Therapeutics
Any Ear Nose or Throat Conditions, With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia
Randomized, prospective, multi-center, double blind placebo-controlled parallel group study of a Placebo Topical Solution versus Cocaine HCl 4% Topical Solution for safety and efficacy, and Cocaine HCl 4% and 10% Topical Solution…
- Trial name
- NCT02500836
- Testing
- Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution
- Where
- United States
- Volunteers
- 646 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
STXBP1 Encephalopathy with Epilepsy
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
This is a prospective, non-interventional, longitudinal study designed to characterize the natural history of STXBP1 related encephalopathy with epilepsy, in participants ≤ <5 years of age.
- Trial name
- NCT05462054
- Sponsor
- Capsida Biotherapeutics, Inc.